PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 25680080-5 2015 ACE inhibitors such as ramipril, captopril, perindopril, quinapril, lisinopril, enalapril, and trandolapril have been documented to ameliorate the above neurodegenerative disorders. trandolapril 95-107 angiotensin I converting enzyme Homo sapiens 0-3 23285665-4 2012 It was found that ACE inhibitors (apo-perindox, prinvil, gopten) caused a significant decrease in the activity of pepsin, while indapen (a diuretic) and glucophage (an antidiabetic drug) increased the activity of this enzyme. trandolapril 57-63 angiotensin I converting enzyme Homo sapiens 18-21 20930708-5 2011 A series of clinical studies have demonstrated a different effect of the angiotensin-converting enzyme (ACE) inhibitors benazepril, captopril, enalapril, lisinopril, perindopril, quinapril, ramipril, spirapril, and trandolapril when routinely ingested in the morning vs. the evening. trandolapril 215-227 angiotensin I converting enzyme Homo sapiens 73-102 20930708-5 2011 A series of clinical studies have demonstrated a different effect of the angiotensin-converting enzyme (ACE) inhibitors benazepril, captopril, enalapril, lisinopril, perindopril, quinapril, ramipril, spirapril, and trandolapril when routinely ingested in the morning vs. the evening. trandolapril 215-227 angiotensin I converting enzyme Homo sapiens 104-107 21574438-1 2011 The study was designed to evaluate effect of trandolapril, an ACE inhibitor, on platelet aggregation in patients with arterial hypertension and impaired glucose tolerance. trandolapril 45-57 angiotensin I converting enzyme Homo sapiens 62-65 21857085-8 2011 The ACE-Is that were used to reduce peripheral vessel resistance included perindopril, lisinopril and trandolapril. trandolapril 102-114 angiotensin I converting enzyme Homo sapiens 4-7 19925416-2 2009 ACE inhibitors of chemical synthesis (captopril, enalapril, ramipril and trandolapril) have been widely used clinically to reduce mortality in patients with heart failure, and in patients with recent myocardial infarction and heart failure or marked left ventricular dysfunction. trandolapril 73-85 angiotensin I converting enzyme Homo sapiens 0-3 19337528-1 2008 Trandolapril is a well known angiotensin converting enzyme (ACE) inhibitor with many cardiovascular (CV) indications. trandolapril 0-12 angiotensin I converting enzyme Homo sapiens 29-58 19337528-1 2008 Trandolapril is a well known angiotensin converting enzyme (ACE) inhibitor with many cardiovascular (CV) indications. trandolapril 0-12 angiotensin I converting enzyme Homo sapiens 60-63 19337528-7 2008 Some of the advantages of trandolapril over other ACE inhibitors are the wide spectrum of patient populations studied, the well established dosage and its proven trough-to-peak effect ratios permitting a safe once-a-day administration. trandolapril 26-38 angiotensin I converting enzyme Homo sapiens 50-53 19847946-6 2007 provides data from INVEST (INternational VErapamil-Trandolapril STudy), which shows the particular utility of a CCB and ACE inhibitor combination in bringing elderly hypertensive patients with CAD to goal BP when monotherapy trandolapril 51-63 angiotensin I converting enzyme Homo sapiens 120-123 16466598-1 2006 The results of the Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE trial), involving patients with stable coronary heart disease, demonstrated that the angiotensin-converting enzyme (ACE) inhibitor trandolapril did not reduce cardiovascular mortality, or the incidence of fatal or non-fatal myocardial infarction. trandolapril 224-236 angiotensin I converting enzyme Homo sapiens 89-92 16285075-1 2005 (1) Some angiotensin-converting-enzyme inhibitors (ACE inhibitors) reduce mortality in patients with heart failure (captopril, enalapril, ramipril and trandolapril), and in patients with recent myocardial infarction and heart failure or marked left ventricular dysfunction (captopril, ramipril and trandolapril). trandolapril 151-163 angiotensin I converting enzyme Homo sapiens 51-54 16285075-1 2005 (1) Some angiotensin-converting-enzyme inhibitors (ACE inhibitors) reduce mortality in patients with heart failure (captopril, enalapril, ramipril and trandolapril), and in patients with recent myocardial infarction and heart failure or marked left ventricular dysfunction (captopril, ramipril and trandolapril). trandolapril 298-310 angiotensin I converting enzyme Homo sapiens 51-54 16106130-3 2005 One reason trandolapril did somewhat less well in the Prevention of Events With Angiotensin-Converting Enzyme Inhibition trial may be that its patients were very well treated with other effective modalities. trandolapril 11-23 angiotensin I converting enzyme Homo sapiens 80-109 15861352-2 2005 This study was performed to determine the low-dose effects of the angiotensin II receptor blocker losartan and the angiotensin-converting enzyme inhibitor trandolapril on pulse wave velocity (PWV), which predicts cardiovascular morbidity and mortality in hemodialysis patients. trandolapril 155-167 angiotensin I converting enzyme Homo sapiens 115-144 15785163-4 2005 The Prevention of Events with Angiotensin-Converting Enzyme Inhibition trial studied the effect of adding the angiotensin-converting enzyme inhibitor trandolapril to a contemporary therapeutic regimen of patients with stable coronary artery disease and preserved left ventricular function. trandolapril 150-162 angiotensin I converting enzyme Homo sapiens 30-59 15618070-0 2005 The long-term impact of the angiotensin-converting enzyme inhibitor trandolapril on mortality and hospital admissions in patients with left ventricular dysfunction after a myocardial infarction: follow-up to 12 years. trandolapril 68-80 angiotensin I converting enzyme Homo sapiens 28-57 15528874-1 2004 BACKGROUND: In the COOPERATE trial, the combination treatment of the angiotensin-II receptor blocker losartan and the angiotensin-converting-enzyme inhibitor trandolapril significantly retarded progression of non-diabetic kidney disease compared with each monotherapy. trandolapril 158-170 angiotensin I converting enzyme Homo sapiens 118-147 15369420-11 2004 In a study comparing an ACE inhibitor (trandolapril), an ARB (losartan), and a combination of the 2 agents (trandolapril and losartan), data showed that all 3 arms reduced BP to the same degree. trandolapril 39-51 angiotensin I converting enzyme Homo sapiens 24-27 15055251-0 2004 Effects of bedtime vs. morning administration of the long-acting lipophilic angiotensin-converting enzyme inhibitor trandolapril on morning blood pressure in hypertensive patients. trandolapril 116-128 angiotensin I converting enzyme Homo sapiens 76-105 15055251-11 2004 In conclusion, bedtime administration of the long-acting ACE inhibitor trandolapril seems to be a safe and effective means of controlling morning BP in hypertensive patients without an excessive fall in nocturnal BP. trandolapril 71-83 angiotensin I converting enzyme Homo sapiens 57-60 14643272-0 2003 The angiotensin converting enzyme inhibitor trandolapril has neutral effect on exercise tolerance or functional class in patients with myocardial infarction and reduced left ventricular systolic function. trandolapril 44-56 angiotensin I converting enzyme Homo sapiens 4-33 14643272-1 2003 AIMS: To study the effect of angiotensin-converting enzyme (ACE) inhibitor trandolapril on exercise tolerance time (ETT) and New York Heart Association (NYHA) classification in patients with reduced left ventricular systolic dysfunction (LVSD) after acute myocardial infarction (AMI). trandolapril 75-87 angiotensin I converting enzyme Homo sapiens 60-63 12618236-6 2003 Treatment with the ACE (angiotensin converting enzyme) inhibitor trandolapril led to a further 2-fold increase in the activation of NF-kappaB and AP-1 when compared to placebo-treated animals with the same MI size (P<0.001). trandolapril 65-77 angiotensin I converting enzyme Homo sapiens 19-22 12618236-6 2003 Treatment with the ACE (angiotensin converting enzyme) inhibitor trandolapril led to a further 2-fold increase in the activation of NF-kappaB and AP-1 when compared to placebo-treated animals with the same MI size (P<0.001). trandolapril 65-77 angiotensin I converting enzyme Homo sapiens 24-53 12852701-0 2003 Trandolapril: a newer angiotensin-converting enzyme inhibitor. trandolapril 0-12 angiotensin I converting enzyme Homo sapiens 22-51 12852701-1 2003 BACKGROUND: Trandolapril is a newer angiotensin-converting enzyme (ACE) inhibitor that is approved by the US Food and Drug Administration for the treatment of hypertension and for use in stable patients who have evidence of left ventricular (LV) systolic dysfunction or symptoms of chronic heart failure within the first 2 days after an acute myocardial infarction (AMI). trandolapril 12-24 angiotensin I converting enzyme Homo sapiens 36-65 12852701-1 2003 BACKGROUND: Trandolapril is a newer angiotensin-converting enzyme (ACE) inhibitor that is approved by the US Food and Drug Administration for the treatment of hypertension and for use in stable patients who have evidence of left ventricular (LV) systolic dysfunction or symptoms of chronic heart failure within the first 2 days after an acute myocardial infarction (AMI). trandolapril 12-24 angiotensin I converting enzyme Homo sapiens 67-70 12852701-5 2003 RESULTS: Trandolapril has a sufficient duration of inhibition of plasma ACE activity to allow once-daily dosing. trandolapril 9-21 angiotensin I converting enzyme Homo sapiens 72-75 12669106-1 2003 The new angiotensin-converting enzyme (ACE) inhibitor trandolapril has been the subject of a broad pharmacological and clinical development program. trandolapril 54-66 angiotensin I converting enzyme Homo sapiens 8-37 12669106-1 2003 The new angiotensin-converting enzyme (ACE) inhibitor trandolapril has been the subject of a broad pharmacological and clinical development program. trandolapril 54-66 angiotensin I converting enzyme Homo sapiens 39-42 12669106-3 2003 Trandolapril has demonstrated potent ACE inhibition, a long plasma half-life and a high degree of lipophilicity. trandolapril 0-12 angiotensin I converting enzyme Homo sapiens 37-40 12669106-6 2003 Trandolapril is one of a few ACE inhibitors with a mean trough:peak ratio of blood pressure reduction with once-daily administration of over 50%. trandolapril 0-12 angiotensin I converting enzyme Homo sapiens 29-32 12425199-3 2002 Aim of the study was treatment of hypertension in patients with DM of both types by the ACE inhibitor trandolapril in dose of 2-4 mg, possibly in combination with the calcium channel blocker verapamil--240 mg. trandolapril 102-114 angiotensin I converting enzyme Homo sapiens 88-91 11929321-3 2002 The pharmacokinetic properties of five newer ACE inhibitors (trandolapril, moexipril, spirapril, temocapril and imidapril) are reviewed in this update. trandolapril 61-73 angiotensin I converting enzyme Homo sapiens 45-48 12421112-1 2002 In well designed studies in patients with mild to moderate hypertension, combinations of the sustained-release (SR) formulation of the nondihydropyridine calcium channel antagonist verapamil 120 to 240 mg/day and the ACE inhibitor trandolapril 0.5 to 8 mg/day were significantly more effective in reducing sitting systolic blood pressure (SBP) and diastolic blood pressure (DBP) from baseline than placebo. trandolapril 231-243 angiotensin I converting enzyme Homo sapiens 217-220 11687731-6 2001 The effects of antihypertensive drugs were evaluated twice in adults patients with mild to moderate essential hypertension: after two weeks of pharmacological wash-out and after two weeks of treatment with the ACE-inhibitor trandolapril (4 mg), or the non-dihydropyridinic Ca2+ channel blocker verapamil (240 mg), or both (2 mg + 180 mg). trandolapril 224-236 angiotensin I converting enzyme Homo sapiens 210-213 11845579-2 2001 New members of this group of drugs are developed and registered and today in Croatia exist a dozen ACE inhibitors from different pharmaceutical companies like lisinopril, cilazapril, ramipril, trandolapril, enalapril etc. trandolapril 193-205 angiotensin I converting enzyme Homo sapiens 99-102 11274903-3 2001 As no reliable means of reversing impaired blood pressure variation has been established so far, we aimed at assessing the effect of a long-acting angiotensin-converting enzyme (ACE) inhibitor trandolapril on the disturbed circadian blood pressure rhythm in diabetics without hypertension or nephropathy. trandolapril 193-205 angiotensin I converting enzyme Homo sapiens 147-176 11274903-3 2001 As no reliable means of reversing impaired blood pressure variation has been established so far, we aimed at assessing the effect of a long-acting angiotensin-converting enzyme (ACE) inhibitor trandolapril on the disturbed circadian blood pressure rhythm in diabetics without hypertension or nephropathy. trandolapril 193-205 angiotensin I converting enzyme Homo sapiens 178-181 11015024-0 2000 Comparison between the angiotensin II receptor antagonist candesartan cilexetil and the angiotensin-converting enzyme inhibitor trandolapril in microalbuminuria of patients with early diabetic nephropathy. trandolapril 128-140 angiotensin I converting enzyme Homo sapiens 88-117 10694831-1 2000 The effects on glucose metabolism by the beta-blocker atenolol and the angiotensin-converting enzyme (ACE)-inhibitor trandolapril were investigated in a randomised double-blind parallel group study of patients with primary hypertension. trandolapril 117-129 angiotensin I converting enzyme Homo sapiens 102-105 10711571-16 2000 Our recent study has demonstrated a significant improvement in peripheral neuropathy following 12 months of treatment with the ACE inhibitor trandolapril. trandolapril 141-153 angiotensin I converting enzyme Homo sapiens 127-130 10746484-1 2000 AIMS: The aims of this study were to examine the effects of trandolapril, a long acting angiotensin converting enzyme (ACE) inhibitor with high tissue uptake, on insulin sensitivity and lipid concentrations in hypertensive patients with Type 2 diabetes mellitus. trandolapril 60-72 angiotensin I converting enzyme Homo sapiens 88-117 10746484-1 2000 AIMS: The aims of this study were to examine the effects of trandolapril, a long acting angiotensin converting enzyme (ACE) inhibitor with high tissue uptake, on insulin sensitivity and lipid concentrations in hypertensive patients with Type 2 diabetes mellitus. trandolapril 60-72 angiotensin I converting enzyme Homo sapiens 119-122 10421597-5 1999 Patients who fulfilled the criteria for inclusion were randomized to treatment with the ACE inhibitor trandolapril or placebo and were followed up for 2 to 4 years. trandolapril 102-114 angiotensin I converting enzyme Homo sapiens 88-91 10464907-6 1999 The bioavailability among ACE inhibitors varies widely with a range from 11% (trandolapril) to more than 60% (captopril). trandolapril 78-90 angiotensin I converting enzyme Homo sapiens 26-29 10406358-0 1999 Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. trandolapril 24-36 angiotensin I converting enzyme Homo sapiens 10-13 10399995-0 1999 Effect of the angiotensin-converting enzyme inhibitor trandolapril on mortality and morbidity in diabetic patients with left ventricular dysfunction after acute myocardial infarction. trandolapril 54-66 angiotensin I converting enzyme Homo sapiens 14-43 10399995-2 1999 OBJECTIVES: This study evaluated the efficacy of long-term treatment with the angiotensin-converting enzyme (ACE) inhibitor trandolapril in diabetic patients with left ventricular dysfunction after acute myocardial infarction (AMI). trandolapril 124-136 angiotensin I converting enzyme Homo sapiens 78-107 10399995-2 1999 OBJECTIVES: This study evaluated the efficacy of long-term treatment with the angiotensin-converting enzyme (ACE) inhibitor trandolapril in diabetic patients with left ventricular dysfunction after acute myocardial infarction (AMI). trandolapril 124-136 angiotensin I converting enzyme Homo sapiens 109-112 10100083-1 1999 OBJECTIVE: The aim of this study was to evaluate the effect of trandolapril, an angiotensin converting enzyme inhibitor, on blood pressure, forearm blood flow and insulin sensitivity in comparison with nifedipine gastrointestinal therapeutic system. trandolapril 63-75 angiotensin I converting enzyme Homo sapiens 80-109 10100083-9 1999 As forearm blood flow was similar in the two treatment groups at baseline and was unchanged after 8 weeks of therapy, skeletal muscle glucose extraction was significantly greater in the ACE inhibitor treated-group than in the nifedipine comparative group (trandolapril: baseline 21 +/- 2, treatment 24 +/- 3 mg/dl; nifedipine: baseline 18 +/- 3, treatment 16 +/- 2 mg/dl; P < 0.05, trandolapril versus nifedipine treatment). trandolapril 256-268 angiotensin I converting enzyme Homo sapiens 186-189 10100083-10 1999 CONCLUSIONS: During short-term treatment, ACE inhibition with trandolapril was able to moderately improve insulin sensitivity, in comparison with calcium blockade, and this effect appeared to be independent of the haemodynamic action of the drug. trandolapril 62-74 angiotensin I converting enzyme Homo sapiens 42-45 10052485-10 1999 CONCLUSIONS: The antiproteinuric and antihypertensive response of verapamil is less than that of the ACE inhibitor trandolapril in patients with non-diabetic renal disease. trandolapril 115-127 angiotensin I converting enzyme Homo sapiens 101-104 10067131-11 1999 A fix-dose combination of the ACE inhibitor trandolapril with verapamil is now available; it should be reserved for patients whose blood pressure and/or proteinuria can not be adequately controlled with ACE inhibitors. trandolapril 44-56 angiotensin I converting enzyme Homo sapiens 30-33 9872248-0 1998 Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial. trandolapril 56-68 angiotensin I converting enzyme Homo sapiens 41-44 9872248-12 1998 INTERPRETATION: The ACE inhibitor trandolapril may improve peripheral neuropathy in normotensive patients with diabetes. trandolapril 34-46 angiotensin I converting enzyme Homo sapiens 20-23 9829159-2 1998 UNLABELLED: Trandolapril is an orally administered angiotensin converting enzyme (ACE) inhibitor that has been used in the treatment of patients with hypertension and congestive heart failure (CHF), and after myocardial infarction (MI). trandolapril 12-24 angiotensin I converting enzyme Homo sapiens 51-80 9829159-2 1998 UNLABELLED: Trandolapril is an orally administered angiotensin converting enzyme (ACE) inhibitor that has been used in the treatment of patients with hypertension and congestive heart failure (CHF), and after myocardial infarction (MI). trandolapril 12-24 angiotensin I converting enzyme Homo sapiens 82-85 9829159-11 1998 The tolerability profile of trandolapril is similar to that of other ACE inhibitors. trandolapril 28-40 angiotensin I converting enzyme Homo sapiens 69-72 9767545-4 1998 METHODS: The present randomized, open label, parallel group designed study tests the hypothesis that, at similar levels of blood pressure, the combination of an ACE inhibitor, trandolapril (T) with the non-DHPCA, verapamil (V) produces a greater reduction in proteinuria over either agent alone at one year. trandolapril 176-188 angiotensin I converting enzyme Homo sapiens 161-164 9752891-0 1998 Ambulatory blood pressure and urinary albumin excretion in diabetic (non-insulin-dependent and insulin-dependent) hypertensive patients: relationships at baseline and after treatment by the angiotensin converting enzyme inhibitor trandolapril. trandolapril 230-242 angiotensin I converting enzyme Homo sapiens 190-219 9825186-2 1998 To evaluate whether trandolapril, a potent lipophilic ACE inhibitor, affects renal function in severe heart failure, we studied 12 patients with severe heart failure treated with only diuretics and digoxin. trandolapril 20-32 angiotensin I converting enzyme Homo sapiens 54-57 10182194-3 1998 DESIGN AND SETTING: The trandolapril cardiac evaluation (TRACE) study was a prospective placebo-controlled clinical trial designed to determine the long term effect of the oral angiotensin-converting enzyme (ACE) inhibitor trandolapril in postinfarction patients with left ventricular dysfunction. trandolapril 24-36 angiotensin I converting enzyme Homo sapiens 59-62 10182194-3 1998 DESIGN AND SETTING: The trandolapril cardiac evaluation (TRACE) study was a prospective placebo-controlled clinical trial designed to determine the long term effect of the oral angiotensin-converting enzyme (ACE) inhibitor trandolapril in postinfarction patients with left ventricular dysfunction. trandolapril 223-235 angiotensin I converting enzyme Homo sapiens 177-206 9701782-2 1998 The patients maintained their usual diet and sodium intake and received the ACE inhibitor trandolapril at a dose of 2 mg daily for 8 days. trandolapril 90-102 angiotensin I converting enzyme Homo sapiens 76-79 9659797-3 1998 In this study we investigated the arterial baroreflex control of heart rate both in supine rest and during active standing before and after 7 and 30 days of treatment with a new ACE-inhibitor, trandolapril (2 mg per os oid) in 15 mild hypertensive patients. trandolapril 193-205 angiotensin I converting enzyme Homo sapiens 178-181 9579769-2 1998 The angiotensin-converting enzyme (ACE) inhibitor trandolapril, a non-sulfhydryl prodrug which is hydrolysed into trandolaprilat, was studied in 322 hypertensives of African-American descent using a double-blind, randomised, placebo-controlled, parallel study design. trandolapril 50-62 angiotensin I converting enzyme Homo sapiens 4-33 9579769-2 1998 The angiotensin-converting enzyme (ACE) inhibitor trandolapril, a non-sulfhydryl prodrug which is hydrolysed into trandolaprilat, was studied in 322 hypertensives of African-American descent using a double-blind, randomised, placebo-controlled, parallel study design. trandolapril 50-62 angiotensin I converting enzyme Homo sapiens 35-38 9589381-2 1998 This study assessed the acute effect of trandolapril, an ACE inhibitor, on serum erythropoietin (EPO) levels in uremic and hypertensive patients. trandolapril 40-52 angiotensin I converting enzyme Homo sapiens 57-60 9534100-2 1998 OBJECTIVE: To evaluate the influence of a history of arterial hypertension and the level of pretreatment blood pressure on the efficacy of the angiotensin converting enzyme (ACE) inhibitor trandolapril on mortality and morbidity in patients with acute myocardial infarction (AMI) and left ventricular dysfunction. trandolapril 189-201 angiotensin I converting enzyme Homo sapiens 143-172 9534100-2 1998 OBJECTIVE: To evaluate the influence of a history of arterial hypertension and the level of pretreatment blood pressure on the efficacy of the angiotensin converting enzyme (ACE) inhibitor trandolapril on mortality and morbidity in patients with acute myocardial infarction (AMI) and left ventricular dysfunction. trandolapril 189-201 angiotensin I converting enzyme Homo sapiens 174-177 9770740-1 1998 AIM: To investigate clinical efficacy of angiotensin-converting enzyme inhibitor trandolapril and its effects on myocardial function. trandolapril 81-93 angiotensin I converting enzyme Homo sapiens 41-70 9734114-2 1997 SUMMARY: The aim of the present study was to investigate the incidence of adverse effects and the prognostic value of various risk factors in a large population of unselected hypertensive patients treated with the ACE inhibitor trandolapril. trandolapril 228-240 angiotensin I converting enzyme Homo sapiens 214-217 9222948-2 1997 OBJECTIVE: To evaluate the influence of a history of arterial hypertension on the efficacy of the angiotensin converting enzyme (ACE) inhibitor trandolapril in patients with acute myocardial infarction (AMI) and left ventricular dysfunction. trandolapril 144-156 angiotensin I converting enzyme Homo sapiens 98-127 9222948-2 1997 OBJECTIVE: To evaluate the influence of a history of arterial hypertension on the efficacy of the angiotensin converting enzyme (ACE) inhibitor trandolapril in patients with acute myocardial infarction (AMI) and left ventricular dysfunction. trandolapril 144-156 angiotensin I converting enzyme Homo sapiens 129-132 9218197-4 1997 CONCLUSION: A fixed combination of an ACE inhibitor and a calcium channel blocker, in particular the combination of trandolapril and verapamil, is a suitable alternative to existing treatment modalities. trandolapril 116-128 angiotensin I converting enzyme Homo sapiens 38-41 9218208-3 1997 Angiotensin converting enzyme (ACE) inhibitors such as trandolapril can prevent the progression of heart failure and thus improve survival. trandolapril 55-67 angiotensin I converting enzyme Homo sapiens 0-29 9218208-3 1997 Angiotensin converting enzyme (ACE) inhibitors such as trandolapril can prevent the progression of heart failure and thus improve survival. trandolapril 55-67 angiotensin I converting enzyme Homo sapiens 31-34 9269701-7 1997 In the second study eight ambulant patients (proteinuria 7.5 +/- 2.7 g/day) were treated during 6 weeks with the ACE-inhibitor trandolapril 4 mg o.d. trandolapril 127-139 angiotensin I converting enzyme Homo sapiens 113-116 8941256-0 1996 Trandolapril: an ACE inhibitor for treatment of hypertension. trandolapril 0-12 angiotensin I converting enzyme Homo sapiens 17-20 8949315-1 1996 The TRACE (TRAndolapril Cardiac Evaluation) study was designed to determine whether long-term treatment with an ACE inhibitor is beneficial in patients with early post-myocardial infarction cardiac failure. trandolapril 11-23 angiotensin I converting enzyme Homo sapiens 6-9 8677862-0 1996 Angiotensin-converting enzyme inhibition after myocardial infarction: the Trandolapril Cardiac Evaluation Study. trandolapril 74-86 angiotensin I converting enzyme Homo sapiens 0-29 12013487-1 1996 OBJECTIVE: This study was designed to assess the compliance of hypertensive patients with a once-daily regimen of the angiotensin converting enzyme (ACE) inhibitor trandolapril and to evaluate the antihypertensive efficacy of the drug in relation to the time interval between taking the final dose and measuring the blood pressure (BP). trandolapril 164-176 angiotensin I converting enzyme Homo sapiens 118-147 12013487-1 1996 OBJECTIVE: This study was designed to assess the compliance of hypertensive patients with a once-daily regimen of the angiotensin converting enzyme (ACE) inhibitor trandolapril and to evaluate the antihypertensive efficacy of the drug in relation to the time interval between taking the final dose and measuring the blood pressure (BP). trandolapril 164-176 angiotensin I converting enzyme Homo sapiens 149-152 7477219-0 1995 A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. trandolapril 64-76 angiotensin I converting enzyme Homo sapiens 24-53 8845087-1 1995 Trandolapril is a new angiotensin converting enzyme (ACE) inhibitor that effectively lowers blood pressure in doses up to 2 mg. Only a small additional effect is seen with higher doses. trandolapril 0-12 angiotensin I converting enzyme Homo sapiens 22-51 8845087-1 1995 Trandolapril is a new angiotensin converting enzyme (ACE) inhibitor that effectively lowers blood pressure in doses up to 2 mg. Only a small additional effect is seen with higher doses. trandolapril 0-12 angiotensin I converting enzyme Homo sapiens 53-56 8845087-4 1995 Trandolapril has a sustained action that is reflected in long-lasting inhibition of ACE, even after discontinuation of treatment. trandolapril 0-12 angiotensin I converting enzyme Homo sapiens 84-87 8572851-1 1995 The aim of the study was to assess the effects of a one-month treatment period with the ACE inhibitor trandolapril (0.3 mg/kg/day) on the endothelial reactivity in epicardial right coronary arteries (CA) of 26-30 week-old SHRs. trandolapril 102-114 angiotensin I converting enzyme Homo sapiens 88-91 9209537-1 1994 The ACE inhibitor Trandolapril is effective even in high risk patients]. trandolapril 18-30 angiotensin I converting enzyme Homo sapiens 4-7 8166055-2 1994 The TRAndolapril Cardiac Evaluation (TRACE) study is evaluating the effect of angiotensin-converting enzyme inhibition with trandolapril on mortality (overall and cardiovascular) and cardiovascular morbidity in patients surviving myocardial infarction (MI) with reduced left ventricular (LV) function. trandolapril 4-16 angiotensin I converting enzyme Homo sapiens 78-107 7519694-7 1994 Thus, the combination of Ca(2+)-channel blockade by sustained release verapamil and ACE inhibition by trandolapril in insulin-resistant type II diabetic patients with essential hypertension appears to be promising in terms of possible synergistic effects. trandolapril 102-114 angiotensin I converting enzyme Homo sapiens 84-87 7527095-2 1994 Both ACE inhibitors caused dose-dependent decreases in blood pressure and ACE activity, trandolapril being 30- and 400- to 1,000-fold more active than enalapril on blood pressure and ACE activity, respectively. trandolapril 88-100 angiotensin I converting enzyme Homo sapiens 5-8 7527095-3 1994 However, comparison of ACE inhibitory activities of the diacid forms of trandolapril and enalapril, i.e., trandolaprilat and enalaprilat, measured in vitro on various tissues, showed that trandolaprilat was only three- to fivefold more active than enalaprilat. trandolapril 72-84 angiotensin I converting enzyme Homo sapiens 23-26 7527095-4 1994 To understand the reasons for such discrepancies between ex vivo effects of ACE inhibitors and in vitro actions of their diacid metabolites, we measured the lipophilicities of the compounds and investigated the possibility that trandolapril could display an ACE inhibitory effect by itself. trandolapril 228-240 angiotensin I converting enzyme Homo sapiens 258-261 7527095-6 1994 In addition, trandolapril was practically as active in vitro as its diacid metabolite (IC50 = 2.5 vs. 1.35 nM) in inhibiting ACE activity in the aorta, whereas enalapril was practically devoid of any effect (IC50 = 240 nM). trandolapril 13-25 angiotensin I converting enzyme Homo sapiens 125-128 7527095-7 1994 Measurements of relative affinities of inhibitors or metabolites for purified human renal ACE showed that trandolapril displayed about 20% of the affinity of its diacid metabolite (IC50 = 15 vs. 3.2 nM); enalaprilat affinity (34 nM) was within the same range as those of trandolapril and trandolaprilat, whereas enalapril displayed a very low affinity for the purified enzyme (IC50 = 50 microM). trandolapril 106-118 angiotensin I converting enzyme Homo sapiens 90-93 7527100-1 1994 The pharmacokinetics and dose proportionality of trandolapril, a new angiotensin-converting enzyme (ACE) inhibitor, were investigated in 12 healthy male volunteers in a four-way randomized crossover study over the therapeutic dose range, 0.5-4 mg. Trandolapril is rapidly absorbed, with a single elimination half-life (t1/2) of 0.72 h, irrespective of dose. trandolapril 49-61 angiotensin I converting enzyme Homo sapiens 69-98 7527100-1 1994 The pharmacokinetics and dose proportionality of trandolapril, a new angiotensin-converting enzyme (ACE) inhibitor, were investigated in 12 healthy male volunteers in a four-way randomized crossover study over the therapeutic dose range, 0.5-4 mg. Trandolapril is rapidly absorbed, with a single elimination half-life (t1/2) of 0.72 h, irrespective of dose. trandolapril 49-61 angiotensin I converting enzyme Homo sapiens 100-103 7527101-1 1994 The new angiotensin-converting enzyme (ACE) inhibitor trandolapril 2 mg was administered daily for 10 consecutive days to young (mean age +/- SEM 44.1 +/- 2.3 years; n = 10) and elderly (mean age +/- SEM 69.3 +/- 0.9 years; n = 14) patients with mild-to-moderate hypertension. trandolapril 54-66 angiotensin I converting enzyme Homo sapiens 8-37 7527101-1 1994 The new angiotensin-converting enzyme (ACE) inhibitor trandolapril 2 mg was administered daily for 10 consecutive days to young (mean age +/- SEM 44.1 +/- 2.3 years; n = 10) and elderly (mean age +/- SEM 69.3 +/- 0.9 years; n = 14) patients with mild-to-moderate hypertension. trandolapril 54-66 angiotensin I converting enzyme Homo sapiens 39-42 7527102-1 1994 A new, long-acting angiotensin-converting enzyme (ACE) inhibitor, trandolapril, was administered daily for 10 days to 13 patients with chronic renal failure [CRF; creatinine clearance (CLCR) 7-55 ml/min/1.73 m2) and 8 healthy volunteers (CLCR > 80 ml/min/1.73 m2)]. trandolapril 66-78 angiotensin I converting enzyme Homo sapiens 19-48 7527102-1 1994 A new, long-acting angiotensin-converting enzyme (ACE) inhibitor, trandolapril, was administered daily for 10 days to 13 patients with chronic renal failure [CRF; creatinine clearance (CLCR) 7-55 ml/min/1.73 m2) and 8 healthy volunteers (CLCR > 80 ml/min/1.73 m2)]. trandolapril 66-78 angiotensin I converting enzyme Homo sapiens 50-53 7527109-0 1994 Long-term therapy with trandolapril, a new nonsulfhydryl ACE inhibitor, in hypertension: a multicenter international trial. trandolapril 23-35 angiotensin I converting enzyme Homo sapiens 57-60 8227480-1 1993 A double-blind, crossover study was carried out to compare the antihypertensive efficacy of the long-acting ACE inhibitor trandolapril 1 mg administered once daily and 0.5 mg twice daily in 31 patients with mild to moderate essential hypertension. trandolapril 122-134 angiotensin I converting enzyme Homo sapiens 108-111 8480624-0 1993 Pharmacologic profile of trandolapril, a new angiotensin-converting enzyme inhibitor. trandolapril 25-37 angiotensin I converting enzyme Homo sapiens 45-74 8480624-1 1993 Trandolapril is a newly developed angiotensin-converting enzyme (ACE) inhibitor that is rapidly hydrolyzed mainly in the liver to its biologically active metabolite trandolaprilat. trandolapril 0-12 angiotensin I converting enzyme Homo sapiens 34-63 8480624-1 1993 Trandolapril is a newly developed angiotensin-converting enzyme (ACE) inhibitor that is rapidly hydrolyzed mainly in the liver to its biologically active metabolite trandolaprilat. trandolapril 0-12 angiotensin I converting enzyme Homo sapiens 65-68 8480624-6 1993 With repeated once-daily administration of trandolapril, plasma ACE activity was reduced in a dose-dependent fashion, but increasing the dose beyond 2 mg did not further reduce angiotensin II levels, apparently because of the compensatory increase in plasma renin levels. trandolapril 43-55 angiotensin I converting enzyme Homo sapiens 64-67 8480627-1 1993 In this article the clinical experiences with the new non-sulfhydryl angiotensin-converting enzyme inhibitor trandolapril are reviewed. trandolapril 109-121 angiotensin I converting enzyme Homo sapiens 69-98 8382444-5 1993 In this model, neointimal proliferation from arterial injury was inhibited by angiotensin converting enzyme inhibition with trandolapril but only modestly. trandolapril 124-136 angiotensin I converting enzyme Homo sapiens 78-107 8443030-2 1993 The pharmacokinetics and pharmacodynamics of a single dose of trandolapril, an angiotensin converting enzyme (ACE) inhibitor with an active metabolite, trandolaprilat, which is in part further metabolised prior to renal elimination, were evaluated in 31 subjects with a wide range of renal function (creatinine clearance 4-112 ml min-1 1.73 m-2). trandolapril 62-74 angiotensin I converting enzyme Homo sapiens 79-108 8443030-2 1993 The pharmacokinetics and pharmacodynamics of a single dose of trandolapril, an angiotensin converting enzyme (ACE) inhibitor with an active metabolite, trandolaprilat, which is in part further metabolised prior to renal elimination, were evaluated in 31 subjects with a wide range of renal function (creatinine clearance 4-112 ml min-1 1.73 m-2). trandolapril 62-74 angiotensin I converting enzyme Homo sapiens 110-113 7512472-2 1993 Among the physicochemical, pharmacokinetic and pharmacodynamic properties that differentiate trandolapril from other angiotensin converting enzyme (ACE) inhibitors, the most clinically relevant ones are those that contribute to the long duration of action of the drug. trandolapril 93-105 angiotensin I converting enzyme Homo sapiens 117-146 7512472-2 1993 Among the physicochemical, pharmacokinetic and pharmacodynamic properties that differentiate trandolapril from other angiotensin converting enzyme (ACE) inhibitors, the most clinically relevant ones are those that contribute to the long duration of action of the drug. trandolapril 93-105 angiotensin I converting enzyme Homo sapiens 148-151 7512472-3 1993 The long elimination half-life of trandolapril and its strong lipophilicity, high ACE inhibitor potency and high affinity for the ACE cause the drug to have a long biological half-life. trandolapril 34-46 angiotensin I converting enzyme Homo sapiens 82-85 7512472-3 1993 The long elimination half-life of trandolapril and its strong lipophilicity, high ACE inhibitor potency and high affinity for the ACE cause the drug to have a long biological half-life. trandolapril 34-46 angiotensin I converting enzyme Homo sapiens 130-133 7512472-4 1993 The long duration of action of trandolapril may be demonstrated experimentally; near total ACE inhibition is observed 24 hours after single dose administration and there is significant ACE inhibition 72 hours following drug withdrawal after long term therapy. trandolapril 31-43 angiotensin I converting enzyme Homo sapiens 91-94 7512472-4 1993 The long duration of action of trandolapril may be demonstrated experimentally; near total ACE inhibition is observed 24 hours after single dose administration and there is significant ACE inhibition 72 hours following drug withdrawal after long term therapy. trandolapril 31-43 angiotensin I converting enzyme Homo sapiens 185-188 1414922-0 1992 Trandolapril in hypertension: overview of a new angiotensin-converting enzyme inhibitor. trandolapril 0-12 angiotensin I converting enzyme Homo sapiens 48-77 1414922-1 1992 Trandolapril is a new angiotensin-converting enzyme (ACE) inhibitor that has been extensively investigated in vitro, in animals, in normal volunteers, and in hypertensive patients. trandolapril 0-12 angiotensin I converting enzyme Homo sapiens 22-51 1414922-1 1992 Trandolapril is a new angiotensin-converting enzyme (ACE) inhibitor that has been extensively investigated in vitro, in animals, in normal volunteers, and in hypertensive patients. trandolapril 0-12 angiotensin I converting enzyme Homo sapiens 53-56 1480537-0 1992 Absence of potentiation of the skin response to intradermal bradykinin by a long-acting angiotensin converting enzyme inhibitor, trandolapril, at conventional antihypertensive dosage in human volunteers: a double-blind, randomized, cross-over, placebo-controlled trial. trandolapril 129-141 angiotensin I converting enzyme Homo sapiens 88-117 1480537-1 1992 A double-blind, randomized, cross-over, placebo-controlled study was carried out to determine the extent and duration of potentiation of the action of bradykinin introduced intradermally by a long-acting novel angiotensin converting enzyme (ACE) inhibitor, trandolapril. trandolapril 257-269 angiotensin I converting enzyme Homo sapiens 241-244 1648489-1 1991 The pharmacological activity and safety of the new angiotensin converting enzyme (ACE) inhibitor trandolapril (RU 44570) has been evaluated in ten healthy male volunteers given 2 mg once daily for seven days. trandolapril 97-109 angiotensin I converting enzyme Homo sapiens 51-80 1648489-1 1991 The pharmacological activity and safety of the new angiotensin converting enzyme (ACE) inhibitor trandolapril (RU 44570) has been evaluated in ten healthy male volunteers given 2 mg once daily for seven days. trandolapril 97-109 angiotensin I converting enzyme Homo sapiens 82-85 1648489-1 1991 The pharmacological activity and safety of the new angiotensin converting enzyme (ACE) inhibitor trandolapril (RU 44570) has been evaluated in ten healthy male volunteers given 2 mg once daily for seven days. trandolapril 111-119 angiotensin I converting enzyme Homo sapiens 51-80 1689424-1 1990 The new ACE inhibitor trandolapril was administered to normal volunteers at daily doses of 0.5, 2, and 8 mg for 10 days. trandolapril 22-34 angiotensin I converting enzyme Homo sapiens 8-11 2537217-0 1989 Safety and tolerance of single oral doses of trandolapril (RU 44.570), a new angiotensin converting enzyme inhibitor. trandolapril 45-57 angiotensin I converting enzyme Homo sapiens 77-106 2537217-1 1989 The safety and tolerance of single oral doses of a new angiotensin converting enzyme (ACE) inhibitor, trandolapril have been examined in 90 healthy male volunteers, in a randomised, double blind, placebo-controlled study. trandolapril 102-114 angiotensin I converting enzyme Homo sapiens 55-84 2537217-1 1989 The safety and tolerance of single oral doses of a new angiotensin converting enzyme (ACE) inhibitor, trandolapril have been examined in 90 healthy male volunteers, in a randomised, double blind, placebo-controlled study. trandolapril 102-114 angiotensin I converting enzyme Homo sapiens 86-89 2537217-12 1989 ACE activity was markedly reduced within 30 min after administration of trandolapril, and maximal inhibition was observed from 2-4 h onwards, lasting for up to 24 h after dosing. trandolapril 72-84 angiotensin I converting enzyme Homo sapiens 0-3 33660934-1 2021 Trandolapril, an angiotensin-converting enzyme inhibitor prodrug, needs to be activated by carboxylesterase 1 (CES1) in the liver to exert its intended therapeutic effect. trandolapril 0-12 angiotensin I converting enzyme Homo sapiens 17-46 30773798-11 2019 The combination of low Klotho and high FGF-23 further identifies patients at distinctly elevated risk who derive clinical benefit from the ACE-inhibitor trandolapril. trandolapril 153-165 angiotensin I converting enzyme Homo sapiens 139-142